What was the primary therapeutic intervention evaluated in the LEADER trial?
Adding trastuzumab deruxtecan to endocrine therapy in patients with detectable ctDNA
Adding the CDK4/6 inhibitor ribociclib to adjuvant endocrine therapy in patients with detectable molecular residual disease (MRD)
Switching from tamoxifen to aromatase inhibitor therapy based on ctDNA monitoring results